Patients receiving hematopoietic stem cell transplants often suffer from graft-versus-host disease (GVHD), involving immune-mediated damage to the gastrointestinal (GI) tract. The symptoms of GVHD include nausea, vomiting, diarrhea, and abdominal cramping due to epithelial cell apoptosis and inflammatory leukocyte infiltration into the GI epithelium. One proposed treatment has been tested in mouse models of GVHD for potential therapeutic benefit. This treatment is:

Question

Quizplus · Accepted Answer

Administration of IL-22 has been shown to have therapeutic potential in mouse models of GVHD by promoting gut epithelial regeneration and reducing inflammation in the GI tract. It has also been observed to enhance the proliferation of intestinal stem cells and promote mucus production in the gut, protecting against pathogenic microbes. Thus, administration of IL-22 could be a promising approach for treating GVHD in humans.

Patients Receiving Hematopoietic Stem Cell Transplants Often Suffer from Graft-Versus-Host β\betaβ

Patients Receiving Hematopoietic Stem Cell Transplants Often Suffer from Graft-Versus-Host $\beta$